AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38497241 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 690517 40 mg
Number of subjects: 58
Study 38497241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 38497241 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 690517 (all doses)
Number of subjects: 58
Study 38497241 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 690517 10 mg
Number of subjects: 58
Study 38497241 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 58
Study 38497347 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 23
Study 38497454 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular dominance
Number of subjects: 766
Study 38497454 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular dominance
Number of subjects: 766
Study 38497454 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 766
Study 38497454 — intervention group
Group type: COMPARATOR
Intervention: RV dominance
Number of subjects: 766
Study 38497706 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor human milk
Number of subjects: 483
Study 38497706 — intervention group
Group type: COMPARATOR
Intervention: Preterm infant formula
Number of subjects: 483
Study 38497709 — intervention group
Group type: EXPERIMENTAL
Intervention: ZEN-3694 and ZEN-3791 quantification using LC-MS/MS method
Number of subjects: 0
Study 38497740 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration between pretreatment assessment and Session 1
Number of subjects: 20
Study 38497955 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based patient portal reminders
Number of subjects: 262085
Study 38497955 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 262085
Study 38497955 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 262085
Study 38497987 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Coaching (PC)
Number of subjects: 1209
Study 38497987 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 1209
Study 38497987 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Coaching and Practice Facilitation (PCPF)
Number of subjects: 1209
Study 38497987 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 1209
Study 38497992 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 7736
Study 38497992 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 7736
Study 38498030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)-based smoking cessation smartphone app, 4 weeks intervention
Number of subjects: 206
Study 38498030 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 'thank you' message
Number of subjects: 206
Study 38498084 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) in combination with CHOP (G-CHOP)
Number of subjects: 0
Study 38498084 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (R) with CHOP (R-CHOP)
Number of subjects: 0
Study 38498139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg (subcutaneous)
Number of subjects: 443
Study 38498139 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Risankizumab
Number of subjects: 443
Study 38498140 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0
Study 38498140 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 38498142 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg CM-chitosan (KioMedine)
Number of subjects: 49
Study 38498141 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 964
Study 38498141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive drug) followed by Risankizumab 150 mg
Number of subjects: 964
Study 38498153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystocele patients with SUI
Number of subjects: 0
Study 38498153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck mobility
Number of subjects: 0
Study 38498397 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted distal pancreatectomy (RDP)
Number of subjects: 1672
Study 38498397 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic distal pancreatectomy (LDP)
Number of subjects: 1672
Study 38498406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen (transsphenoidal and transcranial approaches)
Number of subjects: 647
Study 38498406 — intervention group
Group type: COMPARATOR
Intervention: Non-combined regimen
Number of subjects: 647
Study 38498512 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health coaching (PHC) intervention
Number of subjects: 0
Study 38498587 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT program plus standard medical care
Number of subjects: 0
Study 38498587 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care alone (waitlist)
Number of subjects: 0
Study 38498587 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT program
Number of subjects: 0
Study 38498781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention comprising three to five individual self-management sessions, regular reporting of symptoms, and navigation to health care services.
Number of subjects: 503
Study 38498781 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient visits with the physician (control group).
Number of subjects: 503
Study 38498833 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital patient education (PE) programme
Number of subjects: 180
Study 38498833 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face patient education (PE) programme
Number of subjects: 180
Study 38498835 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOS with oral micronized progesterone (200 mg from stimulation Day 1)
Number of subjects: 44
Study 38498876 — intervention group
Group type: COMPARATOR
Intervention: CV gain-framing group
Number of subjects: 691820
Study 38498876 — intervention group
Group type: COMPARATOR
Intervention: Repeated letter group
Number of subjects: 691820
Study 38498876 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care group
Number of subjects: 691820
Study 38498934 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) nucleic acid amplification testing
Number of subjects: 227
Study 38498934 — intervention group
Group type: COMPARATOR
Intervention: Standard throat culture
Number of subjects: 227
Study 38499015 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ND0612 (levodopa-carbidopa 60.0/7.5 mg/mL)
Number of subjects: 381
Study 38499015 — intervention group
Group type: COMPARATOR
Intervention: Oral levodopa-carbidopa
Number of subjects: 381
Study 38499015 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ND0612
Number of subjects: 381
Study 38499238 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-PD progression (defined as initiation of treatment or clinician's intention to treat)
Number of subjects: 477
Study 38499238 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-PD progression rate
Number of subjects: 477
Study 38499238 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of patients experiencing disease progression
Number of subjects: 477
Study 38499238 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for progression
Number of subjects: 477
Study 38499287 — intervention group
Group type: EXPERIMENTAL
Intervention: Microburst VNS (μVNS)
Number of subjects: 33
Study 38499320 — intervention group
Group type: EXPERIMENTAL
Intervention: FUNBALL programme
Number of subjects: 55
Study 38499323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation initiation within 1 hour of septic shock recognition
Number of subjects: 63
Study 38499323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus volume of 10-20 mL/kg
Number of subjects: 63
Study 38499323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive administration of balanced crystalloids at 1 hour
Number of subjects: 63
Study 38499323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive administration of balanced crystalloids at 24 hours
Number of subjects: 63
Study 38499358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 82
Study 38499358 — intervention group
Group type: COMPARATOR
Intervention: Oral acetaminophen
Number of subjects: 82
Study 38499450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplementation
Number of subjects: 65
Study 38499450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 38499457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pracinostat plus azacitidine (AZA)
Number of subjects: 406
Study 38499457 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus azacitidine (AZA)
Number of subjects: 406
Study 38499501 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical advances in ex vivo lung perfusion (EVLP) including repositioning donor lungs, perfusate adsorption/filtration, enrichment with plasma and nutrients, low-flow and pulsatile perfusion, positive outflow pressure, personalized ventilation strategies, and negative pressure ventilation.
Number of subjects: 0
Study 38499753 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 2
Study 38499753 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2
Study 38499943 — intervention group
Group type: EXPERIMENTAL
Intervention: EOI block with 40 ml 0.25% bupivacaine after anesthesia induction
Number of subjects: 0
Study 38499943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 38499943 — intervention group
Group type: EXPERIMENTAL
Intervention: EOI block group
Number of subjects: 0
Study 38499943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38500051 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual pulmonary rehabilitation (PR) via video conference
Number of subjects: 14
Study 38500051 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual pulmonary rehabilitation (PR) via pre-recorded video
Number of subjects: 14
Study 38500163 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIPA intervention
Number of subjects: 160
Study 38500166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist integrated MOUD clinical model (PrIMO)
Number of subjects: 0
Study 38500183 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback (AF)-based intervention
Number of subjects: 5
Study 38500184 — intervention group
Group type: EXPERIMENTAL
Intervention: EMONO consumers (339 patients)
Number of subjects: 993
Study 38500184 — intervention group
Group type: EXPERIMENTAL
Intervention: EMONO consumers
Number of subjects: 993
Study 38500184 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with SUD
Number of subjects: 993
Study 38500190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-facilitated medication reviews with feedback on medication issues and recommendations to physicians.
Number of subjects: 0
Study 38500190 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a physician-pharmacist collaborative care intervention.
Number of subjects: 0
Study 38500209 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan-enriched oat bread
Number of subjects: 22
Study 38500209 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study 38500236 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction tool for estimating 1-year mortality risk among hospitalized patients with dementia
Number of subjects: 235000
Study 38500236 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort of clinical prediction tool
Number of subjects: 235000
Study 38500292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsegromab 100 mg
Number of subjects: 168
Study 38500292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsegromab 200 mg
Number of subjects: 168
Study 38500292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsegromab 400 mg
Number of subjects: 168
Study 38500292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 38500476 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib 60 mg on Days 1-7 plus zanubrutinib 80 mg twice daily continuously in 28-day cycle
Number of subjects: 70
Study 38500476 — intervention group
Group type: EXPERIMENTAL
Intervention: Zandelisib plus zanubrutinib
Number of subjects: 70
Study 38500494 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial deprivation and lower-quality caregiving
Number of subjects: 520
Study 38500494 — intervention group
Group type: EXPERIMENTAL
Intervention: General psychopathology in early childhood
Number of subjects: 520
Study 38500494 — intervention group
Group type: COMPARATOR
Intervention: Total symptom count
Number of subjects: 520
Study 38500551 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) levels; specific intervention details not available.
Number of subjects: 0
Study 38500576 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Japan
Number of subjects: 17506
Study 38500576 — intervention group
Group type: COMPARATOR
Intervention: BCG-Russia
Number of subjects: 17506
Study 38500636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota profiles in men with prostate cancer
Number of subjects: 181
Study 38500636 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota profiles in benign individuals
Number of subjects: 181
Study 38500636 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial functions related to gut microbiota
Number of subjects: 181
Study 38500841 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day bismuth quadruple therapy
Number of subjects: 313
Study 38500841 — intervention group
Group type: COMPARATOR
Intervention: 14-day bismuth quadruple therapy
Number of subjects: 313
Study 38501082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural Formulation Interview (CFI) administered in the intervention group
Number of subjects: 0
Study 38501082 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 38501087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Number of subjects: 41
Study 38501087 — intervention group
Group type: COMPARATOR
Intervention: Non-adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Number of subjects: 41
Study 38501187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 772
Study 38501187 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 772
Study 38501214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation group (Pao2 of 60 mm Hg)
Number of subjects: 726
Study 38501214 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation group (Pao2 of 90 mm Hg)
Number of subjects: 726
Study 38501219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib 80 mg once-daily plus nivolumab 3 mg/kg on days 1 and 15 in 28-day cycles
Number of subjects: 41
Study 38501219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib 80 mg plus nivolumab 3 mg/kg
Number of subjects: 41
Study 38501219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivavotinib plus nivolumab
Number of subjects: 41
Study 38501262 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib maintenance treatment
Number of subjects: 0
Study 38501262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38501300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 8162
Study 38501508 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Attention Model (MAM) - a hybrid care model incorporating a digital tool (mobile app) for self-management and asynchronous review by professionals.
Number of subjects: 360
Study 38501508 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face care model (control group).
Number of subjects: 360
Study 38501690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials for NUT carcinoma
Number of subjects: 0
Study 38501690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials for SMARCA4-DUT
Number of subjects: 0
Study 38501690 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials for SMARCB1-deficient neoplasms
Number of subjects: 0
Study 38501751 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 0
Study 38501751 — intervention group
Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 0
Study 38501895 — intervention group
Group type: EXPERIMENTAL
Intervention: levcromakalim
Number of subjects: 27
Study 38501895 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 27
Study 38501946 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue photodynamic therapy (MB-PDT) performed after percutaneous abscess drainage with laser illumination at a fluence rate of 20 mW/cm.
Number of subjects: 0
Study 38501946 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care abscess management including image-guided percutaneous drainage and antibiotics.
Number of subjects: 0
Study 38501980 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine combined with pregabalin
Number of subjects: 90
Study 38501980 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and placebo capsules (Control)
Number of subjects: 90
Study 38501987 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin-induced shoulder pain
Number of subjects: 30
Study 38501987 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 30
Study 38501987 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia scores
Number of subjects: 30
Study 38501989 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-based approach
Number of subjects: 10314
Study 38501989 — intervention group
Group type: COMPARATOR
Intervention: Human retrieval
Number of subjects: 10314
Study 38502056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (200 mg)
Number of subjects: 8
Study 38502056 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (dose not specified)
Number of subjects: 8
Study 38502074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 81 mg once daily for 6 months
Number of subjects: 80
Study 38502074 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identical pills once daily for 6 months
Number of subjects: 80
Study 38502127 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a web-based decision aid (MyDecision/MiDecisión)
Number of subjects: 350
Study 38502127 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 38502126 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B biomonitoring group
Number of subjects: 2078
Study 38502126 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2078
Study 38502156 — intervention group
Group type: EXPERIMENTAL
Intervention: PLANTS intervention (web-based training for school staff)
Number of subjects: 0
Study 38502156 — intervention group
Group type: COMPARATOR
Intervention: Active comparator group (publicly available sexual and gender minority youths resources or training)
Number of subjects: 0
Study 38502173 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Media-Delivered Melanoma Prevention Program (intervention group)
Number of subjects: 25
Study 38502173 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control condition (control group)
Number of subjects: 25
Study 38502193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin-regulated DARIC33 T cells
Number of subjects: 0
Study 38502193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin withdrawal
Number of subjects: 0
Study 38502193 — intervention group
Group type: EXPERIMENTAL
Intervention: DARIC33 T cells
Number of subjects: 0
Study 38502193 — intervention group
Group type: COMPARATOR
Intervention: DARIC33
Number of subjects: 0
Study 38502193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin dosing schedule
Number of subjects: 0
Study 38502193 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I DARIC33 trial (PLAT-08, NCT05105152)
Number of subjects: 0
Study 38502195 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-10101 (oral), doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID)
Number of subjects: 54
Study 38502195 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-10101 (oral), recommended phase 2 dose was 75 mg BID
Number of subjects: 54
Study 38502198 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 1550
Study 38502268 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Number of subjects: 10
Study 38502268 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 10
Study 38502425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 mg Bid for three months
Number of subjects: 200
Study 38502425 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 200
Study 38502516 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB) mobile app
Number of subjects: 28
Study 38502656 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/MF59
Number of subjects: 132
Study 38502656 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/alum
Number of subjects: 132
Study 38502656 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/MF59 coadministration
Number of subjects: 132
Study 38502656 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/no adjuvant
Number of subjects: 132
Study 38502672 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home body weight support harness system (BWSS)
Number of subjects: 32
Study 38502709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin (Rezzayo)
Number of subjects: 0
Study 38502709 — intervention group
Group type: COMPARATOR
Intervention: Comparator echinocandin
Number of subjects: 0
Study 38502720 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization based on residual Jeopardy Score (rJS) 0
Number of subjects: 903